2023. 11. 02. 15:40

Vermarktungs Name von SRP-9001 (Elevidys) eingefügt


Neuer Titel: Accelerated Approval of SRP-9001Elevidys (SRP-9001) for Children with DMD

Neuer Petitionstext:

Lady's and Gentlemen

As the undersigned of this petition, we would like to speak out in favor of SRP-9001Elevidys (SRP-9001) from Sarepta Therapeutics / Roche being approved quickly in Europe for children with Duchenne muscular dystrophy (DMD) who are able to walk. We believe this approval is urgently needed because every day counts for patients and the fastest possible treatment can mean a significant improvement in the quality of life for patients with DMD.